Liraglutide

CAS.NO: 204656-20-2

Liraglutide 3.0 can reduce glycosylated hemoglobin, and it has been shown to be beneficial to cardiovascular treatment in typeⅡ diabetic patients with atherosclerotic cardiovascular disease with coronary heart disease, ischemic stroke, and peripheral artery disease. 

Product Name Liraglutide
Packing Specification 10g/100g/500g
Appearances White or off-white powder
Activity: NLT 10Unit/mg 70%~130%
Content: 95.0%~105.0% 95.0%~105.0%
Bacterial Endotoxin Less than 10 EU/mg
Residual HCP NMT 10ng/mg
Residual Exogenous DNA NMT 10ng/dose
Macromolecular Potein NMT 0.7%
HPLC Purity ＞98.0%
Storage Conditions -15℃ below, protected from light, sealed.
Liraglutide Application
Used to prepare liraglutide formula injection.

Liraglutide Insulin Recommended Method
Liraglutide treatment easy dissolved in acidic (pH < 2.5), neutral and alkaline conditions, and can be dissolved and clarified above pH7.0.

Insulin Degludec and Liraglutide Transport and Storage Stability
Transportation stability: It is transported in an ice pack to keep it active.
Storage stability: The product can be stored for at least 24 months at -15®C below.

Notice and Disclaimer
Pollution should be avoided during operation.
The product should not be used for diagnosis or treatment of animals or humans.

If you want to know more about liraglutide in type 1 diabetes, please visit our website.

As a biopharmaceutical company, we can offer kinds of Pharmaceutical raw materials for sale, anything you need, please contact us.